The Brain Drug Developer With Two Approvals in Sight Sits 35% Below Its High

Big Tech earnings dominated headlines this week, and the market is too busy dissecting Meta and Tesla to notice a biotech quietly lining up its biggest moment yet. 

This one has two drugs awaiting FDA decisions and a share price that drifted lower with no news attached. Today we break down why that dip looks like a gift, plus the tickers moving after a wild round of earnings.

Praxis Precision Medicines (NASDAQ: PRAX) recently traded around $256, 35% below its 52-week high. That’s a strange place for a company with four late-stage drugs, two of them sitting at the FDA, and a cash pile that funds the whole plan into 2028.

Praxis builds medicines for brain disorders driven by an imbalance in how nerve cells fire, think epilepsy and movement disorders. A string of clinical wins turned it into a rocket ship over the past 3 years.

Now it’s crossing over from “promising pipeline” to “company with products,” and the market is getting jittery at exactly the wrong moment.

A dip with no headline

Praxis Precision Medicines (NASDAQ: PRAX) slid this week, and the company didn’t put out a single announcement to explain it. You’re seeing a stock that has run hard, with two binary events on the calendar, and traders trimming positions before the FDA has its say.

Meanwhile, the Street is moving the other way. JPMorgan just started coverage with an Overweight rating and a $700 price target, which is well north of double where shares trade now.

When a major bank shows up with that kind of conviction and the stock still slips, you’re looking at nerves. The news hasn’t changed.

What management expects next

The calendar is stacked. The FDA’s decision on relutrigine, for rare and severe childhood epilepsies, lands in late December. The decision on ulixacaltamide, for essential tremor, follows at the end of January.

Topline results from EMERALD, a study testing relutrigine across a broader group of epilepsies, are due before year-end.

Management has said it won’t share regulatory updates until those decision dates arrive. That silence leaves room for the market to fill the gap with worry. For you, it means the price is reflecting fear right before the answers show up.

A tremor drug with a comeback story

Ulixacaltamide targets essential tremor, a movement disorder that causes uncontrollable shaking. Its path to the FDA had more plot twists than a prestige drama.

The trial staged a stunning reversal after an independent data monitoring committee review, delivering results so strong the odds of them happening by chance were less than 1 in 10,000.

That’s a data package that speaks loudly, aimed at a large, underserved market. A clean approval would hand Praxis its first big commercial product, and turn a pipeline story into a sales story.

A first for kids with no treatment options

Relutrigine targets developmental and epileptic encephalopathies caused by SCN2A and SCN8A gene variants. Those are rare, brutal epilepsies that hit children early, and there are currently no treatments approved for these specific conditions.

The FDA pushed the decision back 3 months, spooking some holders. Look at why, though. Praxis submitted additional analyses of existing data, and the agency labeled it a “major amendment,” which gave it extra time to review.

No new studies were requested, and the FDA raised no safety or manufacturing concerns. Call it a paperwork delay.

Elsunersen is the sleeper

Elsunersen is a different kind of drug, an antisense therapy designed to dial down the activity of the SCN2A gene at its source. In an earlier part of its trial, it cut monthly seizures by 77% versus placebo in patients with early-onset SCN2A disease.

Numbers like that make neurologists sit up. Elsunersen is now in a Phase 3 study with a readout expected next year, which gives you another catalyst stacked behind the two FDA decisions.

Vormatrigine keeps the door open

Not every swing connects, and Vormatrigine proves it. Its POWER1 trial in focal epilepsy missed its main goal but hit a secondary measure of seizure reduction. Praxis is now restarting a second study, POWER2, to take another shot.

Focal epilepsy is a broad market, so a win would be a meaningful bonus. You aren’t paying for it at today’s price, which makes it pure upside if the second trial delivers.

Behind it all sit two discovery platforms and a research partnership with Ionis that keep feeding the pipeline.

A war chest built for launch

Praxis holds $1.4 billion in cash and investments with essentially no debt. That funds operations into 2028, which covers both FDA decisions, the EMERALD readout, and the early stretch of commercial launches.

That cushion lowers the risk of a surprise share sale right when the company needs to spend on a sales force. There’s more optionality, too.

Approvals could also bring priority review vouchers, which drugmakers can sell for a tidy sum, and Praxis could license out rights to some programs for extra cash.

The valuation gap

The whole company is valued at $7 billion. An analyst puts the combined peak sales potential of ulixacaltamide and relutrigine above $15 billion. You don’t need anywhere near that to justify today’s price.

The average analyst price target sits at more than double the current share price, and the most bullish targets go much higher.

Analysts also expect Praxis to swing to a profit in 2028. When a stock trades far below where its closest followers think it belongs, the market is giving you a discount for sitting through the FDA wait.

Praxis lost $339 million over the past 12 months, and those losses have been getting bigger. On a screener, that reads like a company heading in the wrong direction.

Context flips the picture. Most of that spending is going toward launch preparation, late-stage trials, and building a commercial team for two drugs that could reach the market within months. Praxis is investing ahead of revenue, and it has the cash to do it.

Once sales start, that number should shrink quickly, which is why analysts see profits on the horizon.

FDA risk is the big one. A rejection or another delay on either drug would hit the stock hard, and the extension on relutrigine shows the agency is reading every page closely. This is a binary setup, and the stock will move fast in whichever direction the answer lands.

The Vormatrigine miss is a reminder that not every program works. If EMERALD or the elsunersen Phase 3 disappoints, the “deep bench” story loses some of its shine.

Launches also take time. If early sales come in slowly, Praxis could need more money down the road, which would mean new shares and dilution for you. And this stock is volatile, so size your position carefully. Expect big swings on both good and bad news.

Praxis is sitting between a massive rally and its first commercial launches, and the market is pricing that gap like a coin flip.

With stunning tremor data, an epilepsy drug aimed at kids with no approved options, a fresh Overweight call from a major bank, and enough cash to get through the launches, the odds look tilted in your favor.

I’d buy it ahead of the decisions. The pullback gives you a cleaner entry, the catalysts are close, and the analyst targets suggest plenty of room to run.

What would change my mind is an FDA rejection on either drug or a weak EMERALD readout. If the stock breaks below $200 on company news, step back and reassess.

Entry zone: $240 to $270. Add on weakness toward $220. Target: $400 to $450 over 9 to 15 months. Confidence: high.

Looking to buy? Build a position in the $240 to $270 range before the late-December decision. Keep your size reasonable, because binary events cut both ways.

Already own it? Hold through the decisions. Watch for the EMERALD topline results and the next earnings update for any color on launch readiness.

Main risk to respect: An FDA rejection or delay on either drug would hit the stock hard. Size your position so a bad decision stings without wrecking your portfolio.

That's our coverage for today; thanks for reading! Reply to this email with feedback or any value stocks you want me to check out.

Best Regards,
—Noah Zelvis
Undervalued Edge